Episode Details

Insulet Corporation (PODD) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $801.7M +23.5% (+22.7% constant currency), which cleared the TOP of Insulet's own 20-22% guide. Adjusted EPS $1.66 +41.5% vs a $1.47 bar (+12.9% beat). GAAP EPS $1.37 - the $0.29 gap is recall warranty cost. Adjusted gross margin 72.9%, a company record. FY2026 adjusted EPS guidance was RAISED from more than 25% growth to more than 30%, while the FY2026 U.S. Omnipod revenue guide was CUT from 20-22% to 17-19%. The 8-K was accepted 7:04 a.m. ET on Aug 5 (before the open), so the reaction is in the tape: PODD fell from $166.82 to $133.26 on Aug 5, minus 20.1% in one session on 7.2M shares, setting the 12-month closing low. It closed Aug 7 at $140.12 - down 60.3% from the $352.82 high of Sep 9, 2025. Insulet beat on revenue, beat the adjusted EPS bar by 12.9% ($1.66 vs $1.47), and RAISED its full-year adjusted EPS guidance from more than 25% growth to more than 30% - and the stock fell 20.1% in a single session to a 12-month low. The total company revenue guide was cut by exactly ONE percentage point (21-23% to 20-22% constant currency). One point cost a fifth of the company, so we went looking for what the market actually repriced. It was not 2026; it was the U.S. exit rate. The entire cut is U.S. Omnipod, guided down from 20-22% to 17-19% - while International was RAISED from 26-28% to 30-32%. Do the residual arithmetic nobody published: FY2025 U.S. Omnipod was $1,919.8M; guide that up 17-19% and 2026 lands at $2,246-$2,285M. The first half already did $1,059.7M and the Q3 guide of 14-16% on a $497.1M base gives about $570M. That leaves Q4 at $610-$658M against $567.8M last year - implied growth of just 7-16%, midpoint 11.7%, against a Q4 2025 that grew 28.0%. The cause, per management: type-2 patients churn inside the first 90 days, though past 90 days their retention converges on type 1. About two-thirds of the cut is that one cohort effect. Second angle: adjusted EPS rose 41.5% while H1 free cash flow FELL 36.6%, to $145.4M from $229.4M, with capex up 83.8% for a new Costa Rica plant and a $60-70M recall bill that leaves EPS but not the bank. Third: adjusted gross margin hit a record 72.9% (+320bp) but only 140bp reached operating margin because SG&A grew 33.8% against revenue's 23.5%. We are buyers anyway - at 21.4x earnings, 12.3x EBITDA and 0.5x net debt, the price embeds a far worse outcome than the guide. But it is cheap on earnings and NOT cheap on cash, and we say so. THE CALL: BUY (3/5, THE MARKET REPRICED THE STORY, NOT THE BUSINESS) — base-case value ~$172.0 vs ~$140.12 today. KEY METRICS: - CALL: BUY 3/5, fair value ~$172 vs the $140.12 Aug 7 close (+22.8%). Bull $299, base $173, bear $102. Street: Buy, 50 analysts, avg target $185.18. - Revenue $801.7M +23.5% (+22.7% cc), above its own guide. Adjusted EPS $1.66 vs a $1.47 bar (+12.9%), +41.5% YoY. GAAP EPS $1.37. Adj gross margin 72.9%, a record. - But FY26 U.S. Omnipod guide CUT from 20-22% to 17-19% on type-2 90-day churn. H1 free cash flow $145.4M vs $229.4M, -36.6%. Implied Q4 U.S. growth only 7-16%. What to watch: UP: 90-day type-2 retention improving in the Q3 print; free cash flow turning back up as Costa Rica capex rolls off; the Q4 U.S. number landing at the top of the implied 7-16% band; adjusted gross margin holding above 72%; International sustaining the raised 30-32% guide. DOWN: a THIRD voluntary medical device correction; another U.S. guidance cut in November; a 2027 guide below the mid-teens management flagged; free cash flow still falling once the plant is finished; competitive entrants (Medtronic, Tandem, Beta Bionics) taking share in 2027. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.